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ABSTRACT: Oral candidiasis is a very common oral condition
among susceptible individuals, with the main causative organism
being the fungus Candida albicans. Current drug delivery systems
to the oral mucosa are often ineffective because of short drug/
tissue contact times as well as increased prevalence of drug-
resistant Candida strains. We evaluated the potency of saturated
fatty acids as antifungal agents and investigated their delivery by
novel electrospun mucoadhesive oral patches using agar disk
diffusion and biofilm assays. Octanoic (C8) and nonanoic (C9)
acids were the most effective at inhibiting C. albicans growth on
disk diffusion assays, both in solution or when released from
polycaprolactone (PCL) or polyvinylpyrrolidone/RS100 (PVP/
RS100) electrospun patches. In contrast, dodecanoic acid (C12)
displayed the most potent antifungal activity against pre-existing C.
albicans biofilms in solution or when released by PCL or PVP/RS100 patches. Both free and patch-released saturated fatty acids
displayed a significant toxicity to wild-type and azole-resistant strains of C. albicans. These data not only provide evidence that
certain saturated fatty acids have the potential to be used as antifungal agents but also demonstrate that this therapy could be
delivered directly to Candida-infected sites using electrospun mucoadhesive patches, demonstrating a potential new therapeutic
approach to treat oral thrush.
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■ INTRODUCTION
Forming part of the normal oral microbial flora, Candida
albicans is a human commensal fungal organism that can be
detected in the oral cavity of approximately half of all healthy
individuals.1 A balance exists between the oral microbial
community and host immunity that maintains many organisms
in their commensal state. This balance can be disrupted by
several factors such as the prolonged use of antibiotics
reducing the number of oral bacteria, leading to microbial
dysbiosis and the unchecked growth of C. albicans on the
surface of the oral mucosa that manifests clinically as
pseudomembranous or erythematous candidiasis where
Candida penetrate the oral epithelium, leading to tissue
damage.2 Individuals at risk of transient or chronic
immunosuppression such as those receiving corticosteroids,
immunotherapy, or chemotherapy, or those with HIV infection
or salivary gland dysfunction (Sjögren’s syndrome) are also
highly susceptible to opportunistic Candida mucosal infection
where the incidence of oral candidiasis for these patients can
be as high as 95%.3−5 Indeed, C. albicans infections among the
immunocompromised are increasing and are now a leading
cause of nosocomial infections in the United States.6
Environmental factors also play a role in oral Candida infection
where smoking is heavily linked with chronic hyperplastic
candidiasis, a condition that is associated with premalignant
lesions that have a high risk of transformation to oral cancer.7
Excessive C. albicans growth is also a common problem for
denture wearers where the organism is able to form a biofilm
between the denture and the hard palate, clinically known as
chronic atrophic candidiasis or denture stomatitis, which
causes significant Candida-mediated mucosal tissue damage.8
At present, candidiasis is treated with a number of antifungal
agents such as nystatin or with azoles such as miconazole and
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fluconazole. Worryingly, research shows that C. albicans has
become increasingly resistant to these common antifungal
drugs,9,10 so finding alternative treatments to overcome
antifungal resistance is of paramount importance.
Some alternative antifungal therapies that have been
explored include the use of surfactants,11,12 synthetic
peptides,13−15 and fatty acids.16 The size, hydrophilicity, and
charge of these molecules determine how they interact with the
C. albicans cell wall, inhibiting the cell growth and reducing the
viability or the biofilm formation.12 An issue with surfactants
and some peptides is their relatively high toxicity to
mammalian cells, whereas fatty acids have been used as
antimicrobial agents in food and dermatological products for
many years and their toxicity to human cells is reported to be
relatively low.17 Indeed, many fatty acids, including those
naturally secreted by microbes, have been shown to display
antifungal properties.18,19 While a number of fungal species
appear to have evolved detoxification mechanisms for fatty
acids, these do not appear to be present in Candida.20
However, the potential for the treatment of oral candidiasis
using short-to-medium-chain fatty acids remains relatively
unexplored.
Another key consideration is the delivery method of
antifungal compounds. The majority of antifungal drugs are
delivered orally and are therefore delivered to lesion sites via
the circulation, even for the treatment of localized mucosal
Candida infection. Such a therapy often causes undesirable side
effects such as headaches, nausea, abdominal pain, vomiting,
and diarrhea.21 For topical treatment, current antifungal
delivery options include creams, gels, mouthwash solutions,
or oral lozenges.22 These preparations provide good initial
coverage but are severely limited by their quick removal from
the mucosal surface to the alimentary canal by saliva flow,
restricting prolonged drug availability. Therefore, a delivery
system that is able to retain the antifungal compound at the
disease site and release its therapeutic load over a protracted
time period would be of great benefit.
We have recently developed mucoadhesive electrospun
patches for therapeutic use in oral medicine.23−25 These
patches are able to release drugs in vivo, are well tolerated by
humans, and are currently in phase two clinical trials for the
treatment of oral lichen planus. Electrospinning is a versatile
fiber-manufacturing technique that combines polymers,
solvents, and other molecules into microscale fibers that can
be collected as mesh-like patches with a high surface area for
drug availability and adhesion to the oral mucosa.26 Common
polymers used in the manufacture of electrospun patches
include polycaprolactone (PCL) and polyvinylpyrrolidone
(PVP) as these are known to be highly compatible with this
spinning technology, are nontoxic, and have been approved by
the Food and Drug Administration (FDA) as ingredients in
multiple pharmaceutical products for human use, allowing a
quick route to clinical use. For the different clinical forms of
mucocutaneous oral candidiasis, a mucoadhesive electrospun
patch could not only deliver the antifungal over a prolonged
period of time at the disease site but also act as a protective
barrier for painful lesions. Consequently, combining the
electrospun delivery system with an antifungal compound
would provide many benefits for patients with oral candidiasis.
Here, we identify short-to-medium-chain fatty acids with
potent antifungal properties and report their successful
incorporation into and release from electrospun patches with
effective antifungal activity.
■ MATERIALS AND METHODS
Electrospinning Conditions and Electrospun Patch Produc-
tion. Electrospinning methods including solution preparation and
patch production for both PCL and PVP/RS100 patches were
performed as previously described by Santocildes et al.23 Briefly, PCL
(Mw 80 kDa; Sigma-Aldrich, Poole, UK) was added at 10 wt % to a
solution of dichloromethane/N,N-dimethylformamide (93:7 w/w %;
Thermo Fisher Scientific, Altrincham, UK) and mixed at room
temperature until dissolved. PVP (Kollidon 90 F, Mw 1000−1500
kDa; BASF, Cheadle, UK) at 10 wt % and Eudragit RS100 (Mw 32
kDa; Evonik Industries AG, Essen, Germany) at 12.5 wt % were
dissolved in 97% w/w ethanol prepared in deionized water at room
temperature. In this study, short-to-medium-chain fatty acids
including butanoic (C5), hexanoic (C6), heptanoic (C7), octanoic
(C8), nonanoic (C9), decanoic (C10), undecanoic (C11), or
dodecanoic (C12) (all from Sigma-Aldrich, Poole, UK) were added
to the polymer dope solutions at a concentration of 0.2 M prior to
spinning. Spinning conditions were 17 kV, 3 mL/h with a 15 cm tip-
to-collector distance. 1H NMR spectroscopy was used to show that
solvents were absent in the final composition of patches (Figure S1).
Scanning Electron Microscopy. Samples were analyzed by
scanning electron microscopy (SEM) as previously described.23
Electrospun patches were sputter-coated with gold (5 nm thickness)
and imaged using a Philips XL20 scanning electron microscope using
an emission current of 15 kV.
Nuclear Magnetic Resonance To Measure Fatty Acid
Content of PCL Electrospun Patches. Proton (1H) nuclear
magnetic resonance (NMR) spectra of fatty acids and PCL
electrospun patches dissolved in 1 mL of deuterated chloroform
(CDCl3) and sealed in a 5 mm tube were recorded using an AVANCE
III or AVANCE III HD spectrometer (Bruker, Coventry, UK) at 298
K and 400.2 or 500.13 MHz. The quantitative spectra were recorded
with eight transients using a 90° pulse and a relaxation delay of 40 s
(having previously determined the longest T1 within the mixtures to
be ∼6.5 s), over an acquisition window of 20 ppm and 64k acquisition
points. The spectra were analyzed using TopSpin version 3.2 software
(Bruker, Coventry, UK). The 1H NMR peaks are representative of the
number of hydrogens present at a particular resonance, where the
normalized integrated signals give the relative number of hydrogens at
a particular resonance. By comparing the normalized integrals of
distinguishable PCL signals versus fatty acid signals, the mole ratio of
the two components was calculated, and thereby, the mass
concentration of fatty acid present in the PCL electrospun fibers
was established.
Gas Chromatography To Measure Fatty Acid Content in
PVP/RS100 Electrospun Patches. Electrospun PVP/RS100
patches were weighed and dissolved in 1 mL of 97% (v/v) ethanol.
Standards of the fatty acids were also prepared in 97% (v/v) ethanol,
ranging from 0.01 to 1 M. An Agilent DB-WAX-UI (30 m × 0.25 mm
× 0.25 μm) column was used with helium flowing through the
column at 1.2 mL min−1 with a pressure of 9.15 psi. The injection
volume of the sample was 1 μL, and the temperature of the column
was increased from 50 to 250 °C at 10 °C min−1 intervals. The mass
spectrometer scan range was between 25 and 500 m/z.
Strains and Growth Conditions. The C. albicans wild-type
strains used were SC5314 (provided by Dr Stephen Saville, University
of Texas at San Antonio, USA) and BWP17 (provided by Prof. Julian
Naglik, Kings College London, UK). The azole-resistant clinical strain
CAR17 was provided by Prof. David Williams (Cardiff University,
UK). Candida auris strain 8971, Candida tropicalis strain 3111 (both
National Collection of Pathogenic Fungi, Public Health England,
UK), and Candida glabrata strain OM146/89 (Sheffield Teaching
Hospitals NHS Foundation Trust, UK) were also used. All strains
were cultured on 1% w/v yeast extract, 2% w/v peptone, and 2% w/v
dextrose (YPD; Oxoid, Basingstoke, UK) agar at 37 °C and stored at
4 °C. Two to three colonies of each strain were inoculated in 15 mL
of YPD broth and incubated at 30 °C overnight. The colonies were
then counted and resuspended in phosphate-buffered saline (PBS) or
RPMI-1640 (Sigma-Aldrich, Poole, UK) for further experimentation.
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Fatty Acid Susceptibility Using Agar Disk Diffusion. Agar
disk diffusion tests on YPD agar plates were performed using strains
SC5314, BWP17, and CAR17. Fatty acids with chain lengths of C5 to
C12 were prepared at 0.2 M in dimethyl sulfoxide (DMSO) (Sigma-
Aldrich, Poole, UK); 200 μL of 2 × 105 colony-forming units (CFU)
per milliliter of C. albicans was diluted in PBS and spread across the
agar plate; 20 μL of each fatty acid solution was pipetted onto filter
paper susceptibility disks that were then placed on the C. albicans-
streaked agar plate in triplicate. Fluconazole (5 μg/disk; purchased in
powder form and prepared in DMSO, Sigma-Aldrich, Poole, UK) and
miconazole (10 μg/disk; used as purchased from Thermo Fisher
Scientific, Altrincham, UK) were used as positive controls and DMSO
as the negative control. Agar plates were incubated overnight at 37 °C,
imaged, and the zone of inhibition was measured using Fiji imaging
software (National Institute of Health, Bethesda, USA27). Agar
diffusion was also used to determine the antifungal effects of fatty
acid-containing electrospun patches; here, 12.7 mm diameter disks
were punched from fatty acid-containing patches, placed onto C.
albicans-streaked plates, incubated overnight at 37 °C, and analyzed as
previously described; patches containing no fatty acid were used as
controls.
C. albicans Biofilm XTT Assay. An XTT assay was used to
determine the levels of C. albicans metabolism as a measure of the
biofilm viability.28 C. albicans biofilms were prepared by adding 100
μL of a 1 × 106 CFU/mL suspension of SC5314 in RPMI-1640 into
each well of a 96-well plate and incubating overnight at 37 °C. Wells
were then washed with PBS and incubated for 18 h at 37 °C with a
concentration series of each fatty acid (C7 to C12, prepared in 0.8 M
DMSO as the carrier and further diluted in RPMI-1640) ranging from
0.0015 to 0.4 M. Biofilms treated with equivalent concentrations of
DMSO were used as controls. Biofilms were washed with PBS, and
then 50 μL of sodium 3′-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-
bis-(4-methoxy-6-nitro) benzene sulfonic acid hydrate (XTT; Sigma-
Aldrich, Poole, UK) was added to each well and the plate was
incubated for 1 h, after which the XTT solutions were transferred to a
new plate and OD was measured at 450 nm and 690 nm for
background correction (Infinite 200 Pro, Tecan, Switzerland). The
data were plotted after transformation by nonlinear regression, and
IC50 values were calculated using GraphPad Prism v8 (GraphPad
Software). A modified version of the XTT assay was also used to
measure the effect of fatty acid-containing patches on the C. albicans
biofilm viability. Here, C. albicans biofilms were prepared in poly-L-
lysine-coated 24-well plates using strain SC5314 or CAR17. C.
albicans (1 × 106 CFU in RPMI-1640) were added to each well, and
the plates were incubated overnight at 37 °C. Wells were washed with
PBS, and then fatty acid-containing electrospun disks (12.7 mm ø)
were placed in each well, followed by 200 μL of RPMI-1640; disks
containing no fatty acid were used as controls. Following incubation
at 37 °C for 18 h, the liquid in each well was removed and 200 μL of
XTT reagent was added to each well and incubated for 1 h, after
which the XTT reagent was removed to a new plate, OD measured,
and data analyzed as previously described.
Fluorescence Microscopy of the Biofilm Viability. Biofilms
were prepared and treated with fatty acid preparations as previously
described. Biofilms were then washed and incubated with the Live/
Dead BacLight viability kit (Thermo Fisher Scientific, Altrincham,
UK) according to the manufacturer’s instructions. Microscopy images
were acquired using an Axiovert 200 M inverted fluorescence
microscope supported with AxioVision software (Zeiss, Oberkochen,
Germany).
Statistics. Statistical analysis was undertaken using GraphPad
Prism v8.0 (GraphPad Software). All data are expressed as mean ±
standard deviation (SD) of at least three independent experiments,
each performed in triplicate unless otherwise stated. Group-wise
Figure 1. Saturated fatty acids in DMSO solution ranging from butanoic (C5) to dodecanoic (C12) at 0.2 M loaded onto filter disks inhibit C.
albicans strains streaked on agar plates. Fluconazole (0.8 mM) and miconazole disks (10 μg or 2.4 nmol) were used as positive controls and DMSO
as the negative control. On the wild-type strain (A) SC5314, heptanoic (C7), octanoic (C8), and nonanoic acid (C9) have similar surface area
inhibition zones as fluconazole and miconazole, whereas on the patient-specific strain (B) CAR17, C7, C8, and C9 have even greater inhibition
areas, whereas the commonly used antifungals fluconazole and miconazole do not have significant inhibition zones. Results are mean ± SD (n = 3).
*p < 0.05; **p < 0.01; ***p < 0.001 vs DMSO. (C) Visual representative images of treated agar plates related to data in (A,B).
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comparisons were carried out using ANOVA Kruskal−Wallis test with
Dunn’s post hoc multiple comparison analysis, and differences were
considered significant when p < 0.05.
■ RESULTS
Application of Medium-Chain-Saturated Fatty Acid
Solutions Inhibit C. albicans Yeast Growth. The growth
inhibition properties of a range of fatty acid solutions (used at
0.2 M) were tested on both wild-type (SC5314, BWP17)
strains and an azole-resistant clinical strain (CAR17) of C.
albicans using an agar disk diffusion assay. For SC5314, zones
of growth inhibition that were significantly different from those
of DMSO controls were observed for heptanoic (C7), octanoic
(C8), and nonanoic (C9) acid (p ≤ 0.05), with octanoic and
nonanoic acid showing similar levels of inhibition to that of the
commonly used clinical antifungal drugs, fluconazole and
miconazole (Figure 1A,C). Similar data were observed for
strain BWP17 that appeared to be even more susceptible to
treatment with octanoic and nonanoic acids than the SC5314
strain (Figure S2). The CAR17 strain was confirmed as being
azole-resistant as treatment with either fluconazole or
miconazole failed to inhibit C. albicans growth (Figure
1B,C).29,30 In contrast, significant zones of inhibition were
observed upon treatment with fatty acids ranging from
hexanoic (C6) to decanoic (C10) acid (p ≤ 0.01; Figure
1B,C). We next extended these studies to test the activity of
some of these fatty acids in other Candida species. Similar to
its effect on C. albicans, nonanoic acid (C9) caused significant
growth inhibition of C. auris (p < 0.01), C. tropicalis (p < 0.01),
and C. glabrata (p < 0.001) in particular when compared to
dodecanoic acid (C12) or DMSO controls (Figure S3). These
data indicate that several short−medium-chain fatty acids have
the ability to markedly inhibit the growth of both susceptible
and azole-resistant forms of C. albicans as well as other disease-
causing Candida species.
Fatty Acid Solutions Reduce the C. albicans Biofilm
Viability in a Chain Length-Dependent Manner. The
agar disk diffusion assay tests the ability of a compound to
inhibit the growth of C. albicans from single-cell yeast forms,
whereas C. albicans in vivo mainly exist as biofilm structures
that are much less susceptible to antifungal treatment.
Therefore, we tested whether fatty acids were able to affect
the viability of preformed in vitro cultured biofilms using an
XTT assay where changes in metabolism are used as a
surrogate measure of the C. albicans viability. The viability of
the SC5314 biofilm was dose-dependent and also decreased in
a fatty acid carbon chain length-dependent manner (Figure
2A). Calculation of the 50% inhibitory concentration (IC50)
showed that undecanoic (C11) and dodecanoic (C12) acids
had approximately 10-fold lower IC50 values than those for
heptanoic (C7) and octanoic (C8) acids (4.7 ± 1.1 and 5.4 ±
1.3 for C11 and C12 compared to 47.3 ± 1.9 and 47.5 ± 2.7
for C7 and C8, respectively) (Figure 2B). To confirm that the
fatty acids were directly killing C. albicans and not just altering
their cell metabolism or fungistatic, a live/dead fluorescent
stain was performed on 50 mM fatty acid-treated biofilms.
Image analysis showed that decanoic (C10), undecanoic
(C11), and dodecanoic (C12) acids caused significantly (p <
0.001) more cell death as determined by propidium iodide-
positive staining than heptanoic (C7), octanoic (C8), and
nonanoic (C9), as well as medium-only controls (Figure
2C,D). These results are in agreement with those obtained for
the XTT biofilm assay, confirming the chain length association
with Candida killing efficiency. These data also show that
nonanoic (C9) acid, which was the most efficient fatty acid at
killing C. albicans in the agar diffusion assay, was much less
potent at killing a C. albicans biofilm, whereas the opposite was
observed for dodecanoic (C12) acid, which was the most
proficient of all fatty acids tested at reducing the biofilm
viability. Interestingly, fluorescence microscopy revealed that
nonanoic acid mainly killed yeast forms of C. albicans, whereas
dodecanoic acid killed both yeast and hyphal forms within the
biofilm (Figure 2D).
Incorporation of Fatty Acids into Electrospun
Patches. As nonanoic (C9) and dodecanoic (C12) acids
were shown to have the greatest effect on the C. albicans
viability in the agar and biofilm assays, respectively, these fatty
acids were chosen to incorporate into PCL and PVP/RS100
electrospun patches. SEM images show that PCL and PVP/
RS100 patches are composed of a mesh-like network of
microfibers. The placebo patches that contained no fatty acid
displayed fibers of similar width for both PCL and PVP/RS100
patches, although PVP RS100 fibers appeared straighter, flatter,
and more uniform than the PCL fibers (Figure 3). Addition of
nonanoic or dodecanoic acid to the PCL dope produced
electrospun fibers with much smaller diameters, resulting in a
more entangled mesh compared to the placebo PCL patch,
Figure 2. C. albicans strain SC5314 biofilm viability when subjected to
fatty acids’ heptanoic acid (C7) to dodecanoic acid (C12) ranging in
concentration in graph (A) from 400 to 1.56 mM using a metabolic
XTT assay. The data are normalized to untreated controls (100%
viability) and mean ± SD (n = 3). (B) Table showing the IC50 of fatty
acids on the C. albicans SC5314 biofilm. (C) Live/dead image analysis
data of the C. albicans strain SC5314 biofilms treated with 50 mM
fatty acids ranging from C7 to C12 (p < 0.001 for C10−C12
compared to all other conditions, n = 5). (D) Representative
fluorescence live (green)/dead (red) and composite images for
conditions media-only, C9, and C12 applied to biofilms. Scale bar =
50 μm.
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whereas this was not evident when these fatty acids were
incorporated into PVP RS100 fibers (Figure 3).
In the process of electrospinning, the solvent system
evaporates as the fibers are produced. Consequently, it is
feasible that some of the volatile short-chain fatty acids may
also evaporate in the procedure, leading to discrepancies
between the fatty acid concentration in the pre-electrospinning
polymer dope and that in the final electrospun patch.
Therefore, it is important to evaluate the final fatty acid
content in the electrospun patch. NMR spectroscopy was used
to analyze PCL patches as the 1H NMR peaks for PCL and the
fatty acid component did not overlap (Figure S4A,B).
However, the PVP/RS100 patches displayed overlapping 1H
NMR peaks and therefore GC−MS was used as an alternative
quantification method. The mean w/w % concentration of the
fatty acid compared to the total patch weight was 2.2% for
nonanoic (C9) acid and 22% for dodecanoic (C12) acid for
the PCL patches (Figure S4C), compared to 8.1% for
nonanoic (C9) acid and 12% for dodecanoic (C12) acid in
the PVP RS100 patches (Figure S4D). As the fatty acids had
been added as a molar concentration in the solvent system of
the electrospinning solution, the actual percentage mass of
fatty acid to the polymer mass in the polymer dope solution
prior to electrospinning was 28% and 18% for dodecanoic
(C12) acid and 22% and 14% for nonanoic (C9) acid in PCL
and PVP/RS100 solutions, respectively.
Electrospun Patches Containing Fatty Acids Inhibit C.
albicans Growth. An agar disk diffusion assay was used to
test if fatty acids could be released from electrospun patches
and remain inhibitory to C. albicans growth. PCL placebo
patches did not inhibit C. albicans growth, showing that
polymers alone do not affect the C. albicans viability, whereas a
small zone of inhibition was observed for PVP/RS100 patches
(Figure 4A,B). It was noted that the PVP/RS100 patches are
much reduced in diameter at the end of the experiment
compared to their PCL counterparts, even though they were
both the same size (12.7 mm diameter) at the start of the
experiment. This is likely related to the hydrophilicity of the
PVP/RS100 patches, which swell almost instantly when placed
on the agar plate as a consequence of moisture uptake from the
C. albicans lawn, resulting in an increase in volume but
decrease in area, which may give rise to the observed false-
positive effect (Figure 4B). For the PCL patches, both
nonanoic (C9) and dodecanoic (C12) acids displayed greater
zones of inhibition compared to the placebo PCL patches (p <
0.001 and p < 0.01 respectively; Figure 4A). Moreover, the
disk diffusion data clearly show that the released nonanoic acid
is the most potent fatty acid causing a significantly greater zone
of inhibition than dodecanoic acid (C9: 7.2 ± 1.3 mm
compared to C12: 2.3 ± 1.7 mm, p < 0.001; Figure 4A,B).
Similarly, nonanoic acid- and dodecanoic acid-containing
PVP/RS100 patches displayed greater zones of inhibition
compared to placebo patches (p < 0.001 and p < 0.01
respectively; Figure 4A). In contrast to PCL patches,
dodecanoic acid-containing PVP/RS100 patches were equally
as potent at inhibiting C. albicans growth as nonanoic acid-
containing patches. Meanwhile, nonanoic acid-containing PCL
patches were significantly better at inhibiting growth than both
Figure 3. Representative SEM images of PCL and PVP RS100
electrospun patches containing no fatty acid (placebo) or nonanoic
(C9) or dodecanoic (C12) acid. The scale bar in the bottom right
applies to all images.
Figure 4. (A) Inhibition surface areas of PCL and PVP R100 fibers
containing nonanoic (C9) and dodecanoic (C12) acids on C. albicans
(strain SC5314) on streaked agar plates are significantly different to
the respective placebo controls. Results are mean ± SD (n = 3). p-
Values above SD bars are compared to the PCL or the PVP RS100
placebo patch and comparison between PCL and the PVP RS100
patch with the same fatty acid is given. **p < 0.01; ***p < 0.001. (B)
Representative images of agar disk diffusion plates. (C) Representa-
tive SEM images of the electrospun patches once removed from a C.
albicans-streaked agar plate are shown; the round shapes along the
fibers are the yeast Candida cells, which are present in all PCL patch
conditions, even with C9 and C12 content, however, are only present
in the PVP/RS100 placebo patch. Scale bar = 20 μm.
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nonanoic and dodecanoic acid-containing PVP/RS100 patches
(p < 0.01; Figure 4A).
SEM images of the fatty acid-containing electrospun patches
that had been used to inhibit C. albicans growth gave a
comparative view of whether C. albicans yeast cells are still
present among the fibers of the electrospun patches (Figure
4C). In both the PCL and PVP/RS100 placebo patches, yeast
forms of C. albicans can be seen adhering to the polymer fibers
(Figure 4C). In contrast, no C. albicans was observed in either
PCL or PVP/RS100 patches loaded with nonanoic acid, in line
with its antifungal activity. In dodecanoic acid-containing PCL
patches, yeast forms of C. albicans were detected but were
markedly less abundant than in placebo patches, whereas no
Candida were seen in SEM images of dodecanoic acid-
containing PVP/RS100 patches (Figure 4C). The contrast
between the PCL and PVP RS100 SEM images clearly shows
the difference in hydrophilicity between the two polymer
systems; the hydrophilicity of the PVP RS100 patch is greater
with the inclusion of dodecanoic acid than nonanoic acid,
producing a collapsed fibrous structure upon contact with the
moist agar plate surface (Figure 4C).
The effect of the electrospun patches containing nonanoic or
dodecanoic acid on the established C. albicans biofilm viability
(SC5314 and CAR17) was determined using an XTT assay.
The placebo patches caused a slight reduction in the biofilm
viability for both strains tested, especially PVP/RS100 on the
CAR17 strain in which the viability was reduced by 60%,
although this was not statistically different to C. albicans
treated with a medium alone (Figure 5A−D). This reduction
may be due to the presence of the quaternary amine-containing
polymer RS100 in the patch as polycations are known to have
an antifungal effect against Candida.31 Dodecanoic acid (C12)-
containing PCL patches caused a 17-fold reduction in the
SC5314 biofilm viability compared to treatment with PCL
placebo patches (p < 0.001), whereas treatment with nonanoic
acid-containing PCL patches showed no effect (Figure 5A). In
contrast, treatment with nonanoic or dodecanoic acid-
containing PCL patches significantly reduced the biofilm
viability of the azole-resistant CAR17 strain by 80% and 70%,
respectively (p < 0.01; Figure 5B). PVP/RS100 patches loaded
with dodecanoic acid reduced both the SC5314 and the
CAR17 biofilm viability by 82% (p < 0.01, Figure 5C) and by
74% (p < 0.05, Figure 5D) compared to placebo controls,
whereas nonanoic acid-containing PVP/RS100 patches,
although reduced the viability, showed no statistically
significant effect (Figure 5C,D).
■ DISCUSSION
As described above, oral candidiasis is relatively common
amongst immunocompromised individuals, those on long-term
antibiotics, and denture wearers and can cause substantial
tissue damage.32 Topical, local delivery at the site of infection
is preferred to directly target C. albicans growth; however,
current delivery methods are transient with the drug being
quickly removed from the mucosal surface via mastication and
salivary flow. We have recently developed a highly
mucoadhesive oral patch that can attach to mucosal surfaces
for up to 2 h and have used these to deliver the anesthetic
lidocaine25 or the steroid clobetasol-17-proprionate as a means
to treat the autoimmune condition, oral lichen planus.23,24
Here, we examined the effectiveness of delivering antifungal
therapy using similar electrospun patches.
Studies have shown that various fatty acids display antifungal
properties against an array of fungal species, although data
regarding their effects on C. albicans are limited.16 Nearly all of
the previous studies have been performed using C. albicans
strains grown in their yeast form in broth culture. However, it
is widely accepted that C. albicans are present in the oral cavity
Figure 5. Nonanoic (C9) and dodecanoic (C12) acid-loaded PCL and PVP/RS100 electrospun patches reduce the SC5314 and the CAR17 C.
albicans biofilm viability. The following conditions are shown: PCL patches on the (A) SC5314 biofilm and (B) on the CAR17 biofilm, PVP/
RS100 patches on the (C) SC5314 biofilm and (D) on the CAR17 biofilm. Results are mean ± SD (n = 3). *p < 0.05; **p < 0.01 compared to the
placebo electrospun patch.
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as a biofilm, which is a mixture of yeast and hyphal forms
within a dense extracellular matrix. Therefore, in this study we
used two in vitro methods to study C. albicans growth
inhibition; an agar disk diffusion assay and a biofilm assay
determine if fatty acids could prevent C. albicans growth from a
yeast form or affect the viability of a pre-existing biofilm.
Using the agar disk diffusion test, it was found that octanoic
(C8) and nonanoic (C9) acids showed the greatest C. albicans
growth inhibition on both wild-type (SC5314 and BWP17)
and the azole-resistant CAR17 strain. For the wild-type strains,
inhibition levels were similar to the commonly used antifungal
agents fluconazole and miconazole, albeit at higher concen-
trations of fatty acids compared with azoles. Importantly, these
data show, for the first time, that certain fatty acids can inhibit
the growth of azole-resistant strains, which is of great
importance given the rapid rise of antifungal resistance in
many clinical isolates of C. albicans.30 Previous studies showed
that only even-numbered carbon-chain-length fatty acids were
effective against C. albicans.33−36 Therefore, to our knowledge,
this is the first study to show that nonanoic (C9) acid inhibits
C. albicans growth as well as the growth of C. glabrata, C. auris,
and C. tropicalis. Additionally, there are no previously
published agar disk diffusion data for fatty acids on C. albicans.
Other studies using a fatty acid as an anti-C. albicans agent
measured minimum inhibitory concentration (MIC) by broth
turbidity or by colony counting.33−36 Huang et al. showed that
hexanoic, octanoic, and dodecanoic acid all inhibited C.
albicans with a similar potency,33 whiereas both Kabara et al.34
and Bergsson et al.35 reported that decanoic and dodecanoic
acids provided the greatest inhibition, with octanoic acid
producing low inhibitory responses. Hayama et al.36 reported
the MIC of octanoic acid, decanoic acid, and dodecanoic acid
as 34.7, 29.0, and 49.9 mM, respectively on a C. albicans
clinical isolate. Overall, these data suggest that for yeast forms,
the predominant morphological form in these assays, nonanoic
and decanoic acids have the most potent antifungal activity.
The reason for the large zone of inhibition for octanoic
compared to decanoic, undecanoic, and dodecanoic acids in
this study is likely due to its water solubility that is 10-fold
higher than for decanoic acid and as the carbon chain length of
the fatty acid increases the water solubility decreases further.
This increased solubility allows octanoic acid to diffuse further
within the agar, reaching a larger surface area to inhibit C.
albicans growth.
Experiments conducted on preformed biofilms provided a
different perspective. Here, undecanoic and dodecanoic acid
were the most potent C. albicans inhibitors (IC50 5.4 and 4.7
mM, respectively). Only one previous study has conducted
inhibition tests on biofilms, where far lower fatty acid
concentrations were required for a reduction in the biofilm
viability.36 The reason for this may be the use of different C.
albicans strains, the number of CFU used (5 × 103 compared
to 1 × 105 cells/mL used in this study), and the use of crystal
violet staining compared to XTT. Crystal violet stains the
entire biomass (including viable, nonviable cells and
extracellular matrix), whereas XTT measures the cell
metabolism as a surrogate for the viability and has been
shown to have greater experimental reproducibility compared
to crystal violet staining.37,38 Live/dead fluorescence staining
confirmed that the fatty acids directly affected the C. albicans
viability rather than the metabolism. Here, nonanoic acid
showed low potency on the biofilm and appeared to selectively
kill yeast forms, whereas dodecanoic acid caused significant cell
death of both yeast and hyphal forms.
The main molecular mechanism by which fatty acids are
thought to act is through their direct insertion into the fungal
plasma membrane, resulting in increased fluidity, dysregulation
of membrane proteins, and altered hydrostatic turgor pressure
within the cell leading to cytoplasmic disorder and ultimately
cell death.18,35,39 There is no evidence to corroborate our
finding that dodecanoic acid has selectivity for hyphal forms of
C. albicans, although there are reports that certain fatty acids
impact hyphal formation, where McClain et al.40 found that
undecanoic acid prevented hyphal formation by inhibiting
enzymes involved in lipid synthesis. Moreover, dodecanoic
acid was found to affect cAMP-mediated pathways,41 whereas
decanoic acid reduced the expression of the hyphal wall
protein HWP-1,19 both of which lead to reduced hyphal
formation in C. albicans.
There are no previous reports on incorporating fatty acids
into electrospun patches for antimicrobial purposes, although
dodecanoic acid has been incorporated into electrospun
polymer fibers to phase-change the polymer material for
thermal energy storing uses.42,43 Tonglairoum et al.44−46
incorporated the antifungal drug clotrimazole into electrospun
patches that successfully eradicated yeast forms of C. albicans
in broth dilution assays. Therefore, given the potency of
saturated fatty acids as antifungal agents, even for azole-
resistant C. albicans strains, and the applicability of electrospun
patches as mucosal drug delivery vehicles, we reasoned that
these two entities be combined for antifungal therapy.
We selected nonanoic and dodecanoic acid fatty acids
because of their contrasting activities in disk diffusion and
biofilm experiments. Both fatty acids were successfully
electrospun in PCL and PVP/RS100 fibers. There was a slight
morphological change when the fatty acids were incorporated
into the PCL patches compared to PVP/RS100, which is
explained by the different degrees of plasticization of the
polymer fibers. 1H NMR spectroscopy and GC−MS analysis
confirmed fatty acid loading. The relatively volatile nonanoic
acid was found at low levels in the PCL fibers, whereas the less
volatile dodecanoic acid was present at a similar wt % as in the
original polymer dope, which was 22 wt % in the fibers
compared to the 28 wt % in the polymer dope. In contrast, in
the PVP/RS100 fibers, nonanoic acid and dodecanoic acid
were both incorporated at 6 wt % less in the fibers compared to
what had been present in the polymer dope. Reasons for this
were not explored, but the fatty acids will interact differently
with the polymers; for example, hydrogen bonding between
the carboxyl group in dodecanoic acid and esters in poly(D,L-
lactide-co-glycolide) has previously been shown using Fourier-
transform infrared spectroscopy.47 The amide groups in PVP
should hydrogen-bond more strongly to the carboxyl groups of
the fatty acids, which may explain why more nonanoic acid is
incorporated in the PVP/RS100 fibers compared to the PCL
fibers.
Agar disk diffusion tests using nonanoic and dodecanoic
acid-containing electrospun patches produced comparable
inhibition data to that observed with soluble fatty acids
released from filter paper disks. Nonanoic acid release was
found to produce the largest inhibition zones and kill C.
albicans bound to the polymer fibers, particularly for PCL
patches, even though the 1H NMR data showed a lower fatty
acid content, once again indicating that nonanoic acid is the
most potent anti-C. albicans fatty acid for multiplying yeast
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forms. SEM images showed that acid-containing PVP/RS100
patches did not retain their fiber structure compared to fatty
acid-containing PCL patches. This is due to the difference in
hydrophilicity between the two patches where the PVP/RS100
patches rapidly absorb water, resulting in swelling and loss of
the fiber structure, whereas the PCL fibers remain intact.
More informative data, from a clinical perspective, were
obtained in the biofilm experiments using both wild-type and
azole-resistant C. albicans strains. Both PCL and PVP/RS100
patches containing dodecanoic acid displayed a remarkable
reduction in the biofilm viability, suggesting that this fatty acid
is the most attractive for the treatment of oral candidiasis using
mucoadhesive electrospun patches.
■ CONCLUSIONS
The data presented in this study clearly demonstrate that
medium-chain saturated fatty acids are an attractive alternative
antifungal therapy to treat C. albicans compared to current
drugs, for which this organism is becoming increasingly
resistant. Moreover, we show here that dodecanoic acid can
be successfully incorporated and released from mucoadhesive
electrospun patches while still retaining potent antifungal
activity in that it is able to penetrate and kill C. albicans even
within a biofilm. An electrospun patch would therefore be an
ideal vehicle to deliver dodecanoic acid directly to the locally
infected sites for the treatment of many forms of oral
candidiasis, and this might be an applicable technology for
other anatomical sites at the risk of fungal infection including
the vaginal epithelium.
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